38308-92-8

Basic information

• Product Name: Boc-DL-hoMoserine
• Synonyms: Boc-DL-hoMoserine;N-Boc-DL-homoserine
• CAS NO: 38308-92-8
• Molecular Formula: C₉H₁₇NO₅
• Molecular Weight: 219.23498
• Mol File: 38308-92-8.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Boc-DL-hoMoserine(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-DL-hoMoserine(38308-92-8)
• EPA Substance Registry System: Boc-DL-hoMoserine(38308-92-8)

Safety Data

• Hazardous Substances Data: 38308-92-8(Hazardous Substances Data)

Usage

Description

Boc-DL-hoMoserine is a chemical compound derived from the amino acid homoserine, which is a precursor in the biosynthesis of methionine and threonine. It features a tert-butyloxycarbonyl (Boc) protecting group that shields the amino group during peptide synthesis, making it a versatile building block for the preparation of peptides and peptidomimetics. Boc-DL-hoMoserine is significant in the development of pharmaceuticals and biologically active compounds, serving as a valuable tool for researchers and scientists in biochemistry and drug discovery.

Uses

Used in Pharmaceutical Development:
Boc-DL-hoMoserine is used as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, Boc-DL-hoMoserine is utilized as a versatile building block for creating complex organic molecules and compounds.
Used in Peptide Chemistry:
Boc-DL-hoMoserine is used as a protected amino acid in peptide chemistry, allowing for the synthesis of peptides and peptidomimetics with enhanced stability and functionality.
Used in Biochemical Research:
Boc-DL-hoMoserine is employed as a research tool in biochemistry, aiding scientists in understanding the mechanisms of various biological processes and the development of biologically active compounds.
Used in Drug Discovery:
Boc-DL-hoMoserine plays a crucial role in drug discovery, serving as a building block for the creation of potential drug candidates and facilitating the advancement of novel therapeutic agents.

Upstream product

• 1070-19-5 N-(tert-butyloxycarbonyl) azide 
• 1927-25-9 DL-Homoserine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 146514-35-4 (RS)-N-tert-butoxycarbonyl-α-amino-γ-butyrolactone 
• 497-19-8 sodium carbonate 
• 10364-50-8 α-amino-γ-bromobutyric acid 
• 672-15-1 L-homoserine 

Downstream Products

• 79349-56-7 N-tert-butyloxycarbonyl-DL-homoserine benzhydryl ester 
• 120042-12-8 methyl 2-(tert-butoxycarbonylamino)-4-hydroxy-butanoate 
• 38308-93-9 2-tert-butoxycarbonylamino-4-hydroxy-butyric acid benzyl ester 
• 146514-35-4 (RS)-N-tert-butoxycarbonyl-α-amino-γ-butyrolactone 
• 1404380-06-8 C₂₇H₄₀N₂O₅Si 
• 876617-13-9 L-2-(tert-Butoxycarbonylamino)-4-(benzyloxy)butanoic acid 

Relevant articles and documents

Synthesis method of 2,4-diaminobutyric acid derivative

The invention belongs to the field of organic chemistry, and particularly relates to a synthesis method of a 2,4-diaminobutyric acid derivative. According to the synthesis method of the 2,4-diaminobutyric acid and the derivative thereof provided by the invention, homoserine is selected as an initial raw material, the amino and carboxyl of the homoserine are protected firstly, a pht group is introduced through a light delay reaction, and then a final product can be obtained through six steps of benzyl ester removal, pht removal and Boc group removal. According to the invention, the synthetic method provided by the invention has relatively high reaction yield and is convenient for separation and purification; the intermediates obtained in the reaction are all protecting group modified aminoacid derivatives and can be directly used as drug intermediates or raw materials for synthesizing other compounds, so that waste is avoided; and the reaction conditions provided by the invention are mild, and later-period amplification production is facilitated.

TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES AS INHIBITORS OF HBSAG (HBV SURFACE ANTIGEN) AND HBV DNA PRODUCTION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS

The present invention provides tetrahydropyridopyrimidines and tetrahydropyridopyridines having the general formula (I) wherein R1, R2, U, W, X, Y and Z are as described herein, as inhibitors of HBsAg (HBV surface antigen) and HBV DNA production for the treatment and prophylaxis of hepatitis B virus infections.

Structure-activity study of new inhibitors of human betaine-homocysteine S-methyltransferase

Betaine-homocysteine S-methyltransferase (BHMT) catalyzes the transfer of a methyl group from betaine to L-homocysteine, yielding dimethylglycine and L-methionine. In this study, we prepared a new series of BHMT inhibitors. The inhibitors were designed to mimic the hypothetical transition state of BHMT substrates and consisted of analogues with NH, N(CH3), or N(CH 3)2 groups separated from the homocysteine sulfur atom by a methylene, ethylene, or a propylene spacer. Only the inhibitor with the N(CH3) moiety and ethylene spacer gave moderate inhibition. This result led us to prepare two inhibitors lacking a nitrogen atom in the S-linked alkyl chain: (RS,RS)-5-(3-amino-3-carboxypropylthio)-3-methylpentanoic acid and (RS)-5-(3-amino-3-carboxypropylthio)-3,3-dimethylpentanoic acid. Both of these compounds were highly potent inhibitors of BHMT. The finding that BHMT does not tolerate a true betaine mimic within these inhibitors, especially the nitrogen atom, is surprising and evokes questions about putative conformational changes of BHMT upon the binding of the substrates/products and inhibitors.